- Johnson & Johnson (NYSE:JNJ) unit The Janssen Pharmaceutical Companies has submitted a supplemental marketing application to the FDA seeking approval for six-month dosing of paliperidone palmitate. If approved, it will be the first and only long-acting injectable drug for schizophrenia with a twice-yearly regimen.
- The company markets paliperidone palmitate as Invega Sustenna (dosed monthly) and Invega Trinza (dosed every three months).
- https://seekingalpha.com/news/3629520-j-and-j-files-u-s-application-for-twice-yearly-dosing-of-schizophrenia-med
Monday, November 2, 2020
J&J files U.S. application for twice yearly dosing of schizophrenia med
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.